5/9/2013

A Series A funding round has brought in $23 million to Lumena Pharmaceuticals, a California-based biotech firm founded by Pappas Ventures. Proceeds will go toward the development of the company's lead drug candidate for cholestatic liver disease. Lumena plans to conduct midstage trials of the drug in adults with primary biliary cirrhosis and in children with alagille syndrome and progressive familial intrahepatic cholestasis.

Related Summaries